Literature DB >> 22236956

Oesophageal cancer: how radical should surgery be?

C Mariette1, G Piessen.   

Abstract

INTRODUCTION: Oesophagectomy for carcinoma can be viewed as comprising two components: resection of the oesophagus and resection of the enveloping lymphatics. Controversy exists regarding how extensive these two components should be.
METHODS: Through a literature overview, the aim of this educational article is to provide surgeons with arguments to understand which operation is the most oncologically sound according to patient and tumour parameters.
RESULTS: Non-randomised comparative studies evaluating radical lymphadenectomy have reported controversial survival benefit. Independent association found between the number of surgically removed lymph nodes and overall survival is an indirect evidence supporting radical lymphadenectomy. The only phase III trial comparing non-radical transhiatal oesophagectomy with transthoracic oesophagectomy for patients with oesophageal adenocarcinoma found 5-year survival rates of 29% vs. 39%, respectively. Although not statistically significant due to underpowered study, specialists would consider less of an increase in survival to be clinically relevant. For squamous OC, the first small randomised controlled trial comparing 2-field lymphadenectomy to 3-field lymphadenectomy did not found significant 5-year survival difference (48% vs. 66%) and the second one comparing 2-field lymphadenectomy to lymph node sampling identified a survival benefit favoring radical resection (36% vs. 25%).
CONCLUSION: Radical transthoracic oesophagectomy with two-field lymphadenectomy appears to offer an optimal balance between benefits and risks to a majority of OC patients, especially in the growing area of neoadjuvant treatments. Non-radical resection should be probably reserved for patients with a poor general status whereas 3-field lymphadenectomy may be reserved to selected patients with loco-regional disease in experienced hands, surely for patients with upper OC.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22236956     DOI: 10.1016/j.ejso.2011.12.022

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  14 in total

1.  Prognostic value of right upper mediastinal lymphadenectomy in Sweet procedure for esophageal cancer.

Authors:  Zhi-Qiang Wang; Han-Yu Deng; Yang Hu; Yong Yuan; Wen-Ping Wang; Yun-Cang Wang; Long-Qi Chen
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

Review 2.  Chinese expert consensus on mediastinal lymph node dissection in esophagectomy for esophageal cancer (2017 edition).

Authors:  Hui Li; Wentao Fang; Zhentao Yu; Yousheng Mao; Longqi Chen; Jie He; Tiehua Rong; Chun Chen; Haiquan Chen; Keneng Chen; Ming Du; Yongtao Han; Jian Hu; Jianhua Fu; Xiaobin Hou; Taiqian Gong; Yin Li; Junfeng Liu; Shuoyan Liu; Lijie Tan; Hui Tian; Qun Wang; Jiaqing Xiang; Meiqing Xu; Xin Ye; Bin You; Renquan Zhang; Yan Zhao
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

3.  Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy for esophageal cancer in the upper mediastinum.

Authors:  Sylvia van der Horst; Teun Johannes Weijs; Jelle Pieter Ruurda; Nadia Haj Mohammad; Stella Mook; Lodewijk Adriaan Anton Brosens; Richard van Hillegersberg
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

Review 4.  Multimodal treatment of esophageal cancer.

Authors:  Florian Lordick; Arnulf H Hölscher; Karen Haustermans; Christian Wittekind
Journal:  Langenbecks Arch Surg       Date:  2012-09-13       Impact factor: 3.445

5.  Recurrent laryngeal nerve lymph node dissection may not be suitable for all early stage esophageal squamous cell carcinoma patients: an 8-year experience.

Authors:  Shaobin Yu; Jihong Lin; Chenshu Chen; Jiangbo Lin; Ziyang Han; Wenwei Lin; Mingqiang Kang
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

6.  Locally advanced esophageal carcinoma: is there still a role of surgery alone without neoadjuvant treatment?

Authors:  Matthias Reeh; Michael F Nentwich; Samir Asani; Faik G Uzunoglu; Maximilian Bockhorn; Guido Sauter; Thomas Rösch; Jakob R Izbicki; Dean Bogoevski
Journal:  J Gastrointest Surg       Date:  2015-02-05       Impact factor: 3.452

Review 7.  [Limitations of surgery for cancer of the upper gastrointestinal tract].

Authors:  E Karakas; C Oetzmann von Sochaczewski; T Haist; M Pauthner; D Lorenz
Journal:  Chirurg       Date:  2014-03       Impact factor: 0.955

8.  A nomogram prediction model for recurrent laryngeal nerve lymph node metastasis in thoracic oesophageal squamous cell carcinoma.

Authors:  Yu Liu; Zhi-Qiang Zou; Juan Xiao; Mei Zhang; Lei Yuan; Xiao-Gang Zhao
Journal:  J Thorac Dis       Date:  2019-07       Impact factor: 2.895

Review 9.  Radiotherapy for tumors of the stomach and gastroesophageal junction--a review of its role in multimodal therapy.

Authors:  Daniel Buergy; Frank Lohr; Tobias Baack; Kerstin Siebenlist; Stefan Haneder; Henrik Michaely; Frederik Wenz; Judit Boda-Heggemann
Journal:  Radiat Oncol       Date:  2012-11-16       Impact factor: 3.481

10.  Right versus left transthoracic approach for lymph node-negative esophageal squamous cell carcinoma.

Authors:  Qilong Ma; Wengao Liu; Hao Long; Tiehua Rong; Lanjun Zhang; Yongbin Lin; Guowei Ma
Journal:  J Cardiothorac Surg       Date:  2015-09-18       Impact factor: 1.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.